Sanofi (SNY) Non-cash Items (2009 - 2021)

Sanofi (SNY) posted Non-cash Items of $48.7 million for Q4 2021, down 99.04% sequentially from $5.1 billion in Q2 2021.

Sanofi (SNY) Non-cash Items (2009 - 2021) Analysis & Trends

Sanofi has reported Non-cash Items for 13 years, with the latest figure at $48.7 million in Q4 2021.

Quarterly Non-cash Items changed N/A year-over-year to $48.7 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $9.9 billion (changed N/A YoY) and the FY2023 annual result came in at $10.3 billion, up 1055.88% from the prior year.
Non-cash Items retreated to $48.7 million in Q4 2021 per SNY's latest filing, from $5.1 billion in the prior quarter.
Over five years, Non-cash Items peaked at $10.5 billion in Q4 2017 and troughed at -$53.1 million in Q1 2021.
A 5-year average of $3.1 billion and a median of $2.2 billion in 2018 frame the typical range for Non-cash Items.
The sharpest annual moves came in 2017 and 2021: Non-cash Items soared 2245.52% in 2017, then slumped 2303.86% in 2021.
Over 5 years, Non-cash Items stood at $10.5 billion in 2017, then tumbled by 59.86% to $4.2 billion in 2018, then tumbled by 95.89% to $172.8 million in 2019, then jumped by 2655.44% to $4.8 billion in 2020, then slumped by 98.98% to $48.7 million in 2021.
According to Business Quant data, Non-cash Items over the past three periods registered $48.7 million, $5.1 billion, and -$53.1 million for Q4 2021, Q2 2021, and Q1 2021 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Johnson & Johnson	652.20 Bn	631.44 Bn	17.26 Bn
2	AbbVie	469.51 Bn	462.94 Bn	12.70 Bn
3	Merck	376.81 Bn	369.67 Bn	12.21 Bn
4	Novartis Ag	303.04 Bn	295.35 Bn	11.24 Bn
5	Astrazeneca	257.61 Bn	252.71 Bn	12.86 Bn
6	Amgen	237.37 Bn	223.38 Bn	7.24 Bn
7	Gilead Sciences	181.73 Bn	178.55 Bn	6.22 Bn
8	Pfizer	159.66 Bn	147.96 Bn	10.94 Bn
9	Gsk	106.24 Bn	102.07 Bn	8.24 Bn
10	Sanofi	55.07 Bn	47.69 Bn	10.79 Bn

Download Data